A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19

The novel coronavirus 2019-nCoV (SARS-CoV-2) infection that emerged in China in December 2019 has rapidly spread to become a global pandemic. This article summarizes the potential benefits of erythropoietin (EPO) in alleviating SARS-CoV-2 pathogenesis which is now called COVID-19. As with other coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahebnasagh, Adeleh, Mojtahedzadeh, Mojataba, Najmeddin, Farhad, Najafi, Atabak, Safdari, Mohammadreza, Rezai Ghaleno, Hassan, Habtemariam, Solomon, Berindan-Neagoe, Ioana, Nabavi, Seyed Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IMSS. Published by Elsevier Inc. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418647/
https://www.ncbi.nlm.nih.gov/pubmed/32863034
http://dx.doi.org/10.1016/j.arcmed.2020.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418647/
https://www.ncbi.nlm.nih.gov/pubmed/32863034
http://dx.doi.org/10.1016/j.arcmed.2020.08.002

Ejemplares similares